Summit Therapeutics SMMT
NASDAQ SMMT
$16.40 +0.92 (+5.94%)
As of: Sep 29, 2026 · 3:59 PM EDT

Summit Therapeutics (SMMT) Non-Current Deferred Tax Liability (2019 - 2020)

Updated

Summit Therapeutics (SMMT) posted Non-Current Deferred Tax Liability of $2.11 million for Q3 2020.

Analysis

Summit Therapeutics (SMMT) Non-Current Deferred Tax Liability (2019 - 2020) Analysis & Trends

At the end of FY2019, Summit Therapeutics' Non-Current Deferred Tax Liability came in at $2.06 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Summit Therapeutics 12.28 Bn 10.04 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 2.11 Mn
Dec 31, 2019 2.06 Mn
API Access

Summit Therapeutics Non-Current Deferred Tax Liability API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deferred-tax-liability&ticker=SMMT&period=max&api_key=YOUR_API_KEY